Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSan Raffaele University

About this trial

This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.

Eligibility criteria

Qualifiers

All individuals included in the study need to have had a colonoscopy at the time of blood sampling.

Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.

Received standard pathological and endoscopic diagnosis and assessment for cohort assignment

Disqualifiers

Lack of informed consent

Inflammatory bowel disease

Trial design

Treatments tested in this trial

  • BEACON

Treatment groups

1,200 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

4
Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital20132, MilanLombardy, Italy
Prof Giulia Martina Cavestro, MD PhD20132, MilanLombardy, Italy
San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit20132, MilanLombardy, Italy
Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori MilanMI, Italy

Sponsors and collaborators

San Raffaele University

Lead sponsor